Home Stock Earnings Edwards Lifesciences Corporation (EW) may enjoy gains as insiders got busy in the recent days

Edwards Lifesciences Corporation (EW) may enjoy gains as insiders got busy in the recent days

Edwards Lifesciences Corporation (EW) may enjoy gains as insiders got busy in the recent days
AT&T Stock

Edwards Lifesciences Corporation’s recently made public that its CVP, Surgical Structural Heart Chopra Daveen unloaded Company’s shares for reported $0.34 million on Oct 14. In the deal valued at $84.77 per share,4,000 shares were sold. As a result of this transaction, Chopra Daveen now holds 18,911 shares worth roughly $ 1.3 million.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


Then, MUSSALLEM MICHAEL A sold 19,875 shares, generating $1,646,523 in total proceeds. Upon selling the shares at $82.84, the Chairman & CEO now owns 157,353 shares.

Before that, Wood Larry L sold 7,242 shares. Edwards Lifesciences Corporation shares valued at $594,713 were divested by the CVP, TAVR at a price of $82.12 per share. As a result of the transaction, Wood Larry L now holds 202,232 shares, worth roughly $13.86 million.

Oppenheimer downgraded its Edwards Lifesciences Corporation [EW] rating to a Perform from a an Outperform in a research note published on Friday. A number of analysts have revised their coverage, including Mizuho’s analysts, who began to cover the stock in late October with a ‘”a Buy”‘ rating. Barclays began covering EW with “an Overweight” recommendation on October 18, 2022. Jefferies started covering the stock on October 12, 2022. It rated EW as “a Buy”.

Price Performance Review of EW

On Friday, Edwards Lifesciences Corporation [NYSE:EW] saw its stock fall -0.17% to $68.54. On the same session, the stock had its day’s lowest price of $67.37, but rose to a high of $69.98. Over the last five days, the stock has lost -3.29%. Edwards Lifesciences Corporation shares have fallen nearly -47.09% since the year began. Nevertheless, the stocks have fallen -41.60% over the past one year. While a 52-week high of $131.73 was reached on 04/21/22, a 52-week low of $68.03 was recorded on 11/04/22. SMA at 50 days reached $85.48, while 200 days put it at $99.97. A total of 5.66 million shares were traded, compared to the trading of 11.86 million shares in the previous session.

Levels Of Support And Resistance For EW Stock

The 24-hour chart illustrates a support level at 67.28, which if violated will result in even more drops to 66.02. On the upside, there is a resistance level at 69.89. A further resistance level may holdings at 71.24. The Relative Strength Index (RSI) on the 14-day chart is 25.65, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -9.96, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 94.63%. Stochastics %K at 3.83% indicates the stock is a buying.

How much short interest is there in Edwards Lifesciences Corporation?

A steep rise in short interest was recorded in Edwards Lifesciences Corporation stocks on Jul 14, 2022, growing by 0.79 million shares to a total of 6.66 million shares. Yahoo Finance data shows the prior-month short interest on Jun 14, 2022 was 5.87 million shares. There was a rise of 11.86%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 1.08% of the overall stock float, the days-to-cover ratio (short ratio) rose to 2.65.

Edwards Lifesciences Corporation [EW] – Who Are The Largest Shareholders?

In filings from The Vanguard Group, Inc., it is revealed that the company now owns 47,744,472 shares, or roughly 7.70% of the outstanding EW shares. In other words, the investor’s shares have risen by 541,265 from its previous 13-F filing of 47203207.0. Additionally, BlackRock Fund Advisors decreased -3.63% of its stake after which the total value it holdings stand at $2,642,722,651, while SSgA Funds Management, Inc. reduced -0.09% of its stake to hold $2.22 billion in the firm. Over the last quarter, Capital Research & Management Co purchased 253,759 shares of Edwards Lifesciences Corporation, while AllianceBernstein LP bought 2,283,544 shares. At present, Walter Scott & Partners Ltd. is holding 15,174,361 shares valued at $1.25 billion. Wellington Management Co. LLP owned 14,178,936 shares of the company at the time of its most recent 13F filing, worth $1.17 billion.

According to FactSet, Edwards Lifesciences Corporation’s share price will average $92.51 in the next year, based on opinions of analysts polled by the firm. This is up nearly 38.36 percent from its previous closing price of $68.66. Analysts expect Edwards Lifesciences Corporation stock to reach the higher price of $118.00, while the lowest price estimate is $73.00. However, 27 analysts have rated EW stock as an Overweight in their predictions for 2022.


Please enter your comment!
Please enter your name here